NASDAQ:DBVT Stock Quote
6.1750
+2.2650 (57.93%)
Dbv Technologies is a biopharmaceutical company focused on developing innovative therapies for patients with food allergies, particularly peanut allergies
Utilizing its proprietary Systemic Immunotherapy platform, the company aims to create treatments that help desensitize individuals to allergens, ultimately enhancing their quality of life and reducing the risk of severe allergic reactions. By leveraging advanced medical technology and a rigorous clinical development approach, Dbv Technologies strives to bring novel, breakthrough solutions to the field of immunotherapy for food allergies.
| Previous Close | 3.910 |
|---|---|
| Open | 6.030 |
| Bid | 6.150 |
| Ask | 6.180 |
| Day's Range | 5.300 - 6.780 |
| 52 Week Range | 0.4409 - 5.420 |
| Volume | 20,763,682 |
| Market Cap | 340.22M |
| PE Ratio (TTM) | -5.881 |
| EPS (TTM) | -1.1 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 22,080 |
